



FFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.	Confirmation No:	TBA
Serial No.:	10/583,491	Case No.:	ITR0054P
Filed:	June 15, 2006	Art Unit:	TBA
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY		

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Response to Notification of Defective Response

Sir:

In response to the Notification of Defective Response mailed November 19, 2008, submitted herewith is a Sequence Listing (in computer readable and written form) and a Statement In Accordance With 37 CFR §§ 1.821-1.825.

No fee is believed to be due. However, the Commissioner is hereby authorized to charge any additional fees which may be required to deposit account 13-2755.

Respectfully submitted,

Dated: 25 November 2008

By:

Melissa B. Wenk  
Reg. No. 53,759  
Attorney for Applicants

Correspondence Address:

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-2756 Telephone  
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Douglas R. Pohl Date 11/25/2008



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Elisabetta Bianchi et al.		Confirmation No:	TBA	
Serial No.:	10/583,491	Case No.:	ITR0054P	Art Unit:	TBA
Filed:	June 15, 2006		Examiner:	TBA	
For:	A METHOD TO MAKE A PEPTIDE-CARRIER CONJUGATE WITH A HIGH IMMUNOGENICITY				

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**STATEMENT IN ACCORDANCE WITH 37 CFR §§ 1.821-1.825**

Sir:

Enclosed is a Sequence Listing in computer readable and written form. I hereby state that the information recorded in computer readable form of the Sequence Listing is identical to the written form of the Sequence Listing.

Respectfully submitted,

Dated: 25 November 2008

By:

  
Melissa B. Wenk  
Reg. No. 53,759  
Attorney for Applicants

Correspondence Address:

Merck & Co., Inc.  
P.O. Box 2000  
Rahway, NJ 07065-0907  
(732) 594-2756 Telephone  
(732) 594-7790 Facsimile

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By Debra L. Perdue Date 11/25/2008



## SEQUENCE LISTING

<110> Elisabetta Bianchi  
Antonello Pessi  
Marco Finotto  
Paolo Ingallinella

<120> A METHOD TO MAKE A PEPTIDE-CARRIER  
CONJUGATE WITH A HIGH IMMUNOGENICITY

<130> ITR0054P

<140> 10/583,491  
<141> 2006-06-15

<150> 60/530,867  
<151> 2003-12-18

<150> PCT/EP2004/014160  
<151> 2004-12-14

<160> 11

<170> FastSEQ for Windows Version 4.0

<210> 1  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 1  
Cys Gly Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly  
1 5 10 15  
Phe Ile Glu Asn Gly Asn His  
20

<210> 2  
<211> 24  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 2  
Ala Cys Gly Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala  
1 5 10 15  
Gly Phe Ile Glu Asn Gly Glu His  
20

<210> 3  
<211> 22  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 3  
Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile  
1 5 10 15  
Glu Asn Gly Cys Asn His  
20

<210> 4  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 4  
Ser Glu Pro Glu Lys Gln Thr Arg Gly Leu Phe Gly Ala Ile Ala Gly  
1 5 10 15  
Phe Ile Glu Asn Gly Cys His  
20

<210> 5  
<211> 20  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 5  
Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg Gln  
1 5 10 15  
Leu Cys Asn His  
20

<210> 6  
<211> 21  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 6  
Ser Ser Thr Met Gly Ala Arg Ser Met Thr Leu Thr Val Gln Ala Arg  
1 5 10 15  
Gln Leu Cys Asn His  
20

<210> 7  
<211> 29  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 7  
Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu Gly  
1 5 10 15  
Met Ile Asp Gly Gly Cys Gly Lys Lys Lys Lys Asn His  
20 25

<210> 8  
<211> 23  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 8  
Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Trp Glu Gly  
1 5 10 15  
Met Val Asp Gly Cys Glu His  
20

<210> 9  
<211> 16  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 9  
Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Cys Glu His  
1 5 10 15

<210> 10  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 10  
Ala Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Cys Glu  
1 5 10 15  
His

<210> 11  
<211> 17  
<212> PRT  
<213> Artificial Sequence

<220>  
<223> Chemically Synthesized

<400> 11  
Ser Gly Leu Phe Gly Ala Ile Ala Gly Phe Ile Glu Asn Gly Cys Glu  
1 5 10 15  
His